Greg Kalemkerian, MD

---

Authored Items

The Value of Personalized Medicine in Oncology

Letter to Our Readers

Dear Colleague, Personalized Medicine in Oncology (PMO) organizes the vastly complex forces of personalized medicine into an approachable model of cancer care: Identifying the genetic mutations and biological derangements that drive tumors Translating genomics, proteomics, and metabolomics into real-world clinical strategies Anticipating payers’ increasing demands for prior authorization of biological [ Read More ]

Personalized Medicine in Oncology: Providing Insights to Optimally Utilize Personalized Medicine Concepts

May 2013, Vol 2, No 3 - Uncategorized

Dear Colleague, I want to welcome you to this issue of Personalized Medicine in Oncology (PMO) with a few facts concerning personalized medicine (PM): 79% of late-stage oncology pipeline are targeted therapies Molecular profiling is driving many new targeted cancer therapeutics, with over 500 compounds coming soon, and 140 targets [ Read More ]